ZNTL - Zentalis Pharmaceuticals, Inc.
Zentalis Pharmaceuticals, Inc. , a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its lead product candidate includes the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, which is in Phase 2 clinical trial for the treatment of advanced solid tumors; Phase 1/2 clinical trial for the treatment of advanced solid tumors as a monotherapy and in an ongoing Phase 1b clinical trial in combination with chemotherapy in patients with platinum resistant ovarian cancer; and Phase 2 monotherapy trial for a tumor agnostic, predictive biomarker.
As of May 15, 2026: spot at $4.04, ATM IV 161.0%, max pain $2.50, net GEX $2.7K.
- Sector
- Healthcare
- Industry
- Biotechnology
- Market Cap
- $303.6M
- Beta
- 2.00
- 52-Week Range
- 1.13-6.95
- CEO
- Julie Eastland
- Employees
- 166
- IPO Date
- Apr 3, 2020
- Exchange
- NASDAQ
What ZNTL Looks Like to Options Traders Today
IV rank of 40.0% sits near the 1-year median, where strategy choice depends on directional conviction and the event calendar rather than vol regime alone; positive net gamma exposure ($2.7K) means dealers hedge against trend, damping realized volatility and biasing price toward heavy-OI strikes.
What This Page Covers
The ZNTL overview links into per-metric analysis views: max pain, gamma exposure, volatility skew, expected move, options chain, open interest history, and aggregate Greeks. Microstructure data is available on short interest, short volume, fail-to-deliver, and market structure. Corporate data is on fundamentals, earnings, analyst ratings, and insider trading.
Frequently asked ZNTL overview questions
- What is ZNTL?
- ZNTL is the ticker symbol for Zentalis Pharmaceuticals, Inc., a listed security. Zentalis Pharmaceuticals, Inc. , a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Listed on NASDAQ. ZNTL is the equity ticker shown on this page; equity options traders use the security for directional, volatility, and income strategies via the listed options chain.
- What does the ZNTL options snapshot look like today?
- As of May 15, 2026, the ZNTL options snapshot shows spot at $4.04, ATM IV 161.0%, IV rank 40.0%, max pain $2.50, net GEX $2.7K, expected move 46.16%. The full options chain, Greeks by strike and expiration, per-strike open-interest distribution, dealer gamma and delta exposure, and the volatility skew surface are linked from this overview page. Each per-metric route refreshes once per trading session and reflects the most recent close-of-business listed-options state.
- What are ZNTL's key statistics?
- Zentalis Pharmaceuticals, Inc. (ZNTL) carries a market capitalization of $303.6M, beta of 2.00 relative to the broader market, 52-week range of 1.13-6.95. Full income statement, balance sheet, cash flow, and TTM ratio history is on the per-ticker fundamentals page; daily price history and 52-week levels are accessible from the same view. These structural inputs frame how the options market prices implied volatility around earnings windows and capital events.
- What sector or industry does ZNTL belong to?
- Zentalis Pharmaceuticals, Inc. operates in the Healthcare sector, in the Biotechnology industry. Sector classification affects how the ticker correlates with sector ETFs, how it reacts to macro factors like rate moves and commodity prices, and how its options pricing compares to sector peers. Compare ZNTL's implied volatility and skew against sector benchmarks to gauge whether the options market is pricing single-name or systemic risk relative to the broader peer group.
- How current is the ZNTL data on this page?
- The options snapshot above is dated May 15, 2026 and refreshes once per session, with all per-strike Greeks and exposure aggregates recomputed at the daily close. Company-profile fields (sector, industry, market cap, P/E, IPO date) refresh from the vendor feed nightly. Financials and earnings refresh as 10-K and 10-Q filings are parsed (typically within several business days of the actual report). FINRA microstructure data refreshes on the source's cadence (daily for short volume, bi-monthly for short interest, weekly for the OTC volume file, twice-monthly for SEC FTD).